Imperva (IMPV) Tops Q4 EPS by 5c, Q1 & FY16 Guidance Falls Short
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Needham & Company Reiterates Buy Following Imperva's (IMPV) 4Q Beat and Raise
February 4, 2016 6:45 AM ESTNeedham & Company maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $56.00 (from $88.00), following the company's 4Q earnings report. IMPVs $72.7m and $0.20 was comfortably above $68.1m and $0.15 EPS consensus, yet investor expectations were high going into earnings. CY16 old guidance was for $285m, and last night IMPV revised... More
